Difference between revisions of "Migraine"
| Line 14: | Line 14: | ||
==Guidance== | ==Guidance== | ||
| + | === Guidance at registration === | ||
| + | |||
| + | ====Unacceptable==== | ||
| + | Donors taking the following medications should not be accepted onto the register: | ||
| + | Clonidine, Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality). | ||
| + | |||
| + | Otherwise, acceptable. | ||
| + | |||
| + | === Guidance at VT === | ||
====Unacceptable==== | ====Unacceptable==== | ||
Severe, having more than two attacks per month | Severe, having more than two attacks per month | ||
Latest revision as of 15:48, 7 July 2025
Contents
Acceptability at Recruitment
QUALIFIED
Acceptability at CT / Work-Up
QUALIFIED
Individual at Risk
Donor
Explanation of Condition
Intermittent headaches associated with nausea and visual phenomena (aura), such as zig-zag lines or halos.
See also Migraine
Guidance
Guidance at registration
Unacceptable
Donors taking the following medications should not be accepted onto the register: Clonidine, Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality).
Otherwise, acceptable.
Guidance at VT
Unacceptable
Severe, having more than two attacks per month
Requires clonidine as prophylaxis (preventative medication)
Monoclonal antibodies are used for migraine prophylaxis. In the UK, erenumab (aimovig), fremanezumab (ajovy), galcanezumab (emgality) are the monoclonal antibodies licensed for use.
Acceptable
Uses pizotifen (Sanomigran) or beta-blocker as prophylaxis
Discuss with medical officer if unclear.
Pseudonyms or Related Conditions
Version
Version 1, Edition 2
Date of Last Update
1 June 2016
